Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis.
How embodied is action language? Neurological evidence from motor diseases.
Coenzyme Q10 supplementation and multiple sclerosis.
Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.
Does antiretroviral therapy for HIV reduce the risk of developing multiple sclerosis?
Neurodegeneration: From Multiple Sclerosis to Alzheimer's Disease.
Cognitive and Clinical Dysfunction, Altered MEG Resting-State Networks and Thalamic Atrophy in Multiple Sclerosis.
PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions.
Cerebral venous thrombosis in a patient with clinically isolated spinal cord syndrome.
Charcot-Marie-Tooth disease: Genetic and clinical spectrum in a Spanish clinical series.
Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study.
Cognition, cognitive dysfunction, and cognitive rehabilitation in multiple sclerosis.
Predictors and impact of the working alliance in the neuropsychological rehabilitation of patients with multiple sclerosis.
Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance.
Berberine and neurodegeneration: A review of literature.
Translating CESD-20 and PHQ-9 Scores to PROMIS Depression.
The role of N-Glycan modification of TNFR1 in inflammatory microglia activation.
Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients.
Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.
Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease.
Lyme disease associated neuroretinitis - Case report.
Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem.
Whole-body cryostimulation (cryotherapy) provides benefits for fatigue and functional status in multiple sclerosis patients. A case-control study.
Comprehensive Profile of Cardiopulmonary Exercise Testing in Ambulatory Persons with Multiple Sclerosis.
Pages
« first
‹ previous
…
538
539
540
541
542
543
544
545
546
…
next ›
last »